Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    United Therapeutics Corpo...

    NASDAQ: UTHR · Real-Time Price · USD
    288.31
    4.96 (1.75%)
    At close: Jun 16, 2025, 3:59 PM

    United Therapeutics Statistics

    Share Statistics

    United Therapeutics has 45.11M shares outstanding. The number of shares has increased by 1.23% in one year.

    Shares Outstanding

    n/a
    		 45.11M

    Shares Change (YoY)

    n/a
    		 1.23%

    Shares Change (QoQ)

    n/a
    		 0.6%

    Owned by Institutions (%)

    n/a
    		 98.76%

    Shares Floating

    n/a
    		 43.99M

    Failed to Deliver (FTD) Shares

    n/a
    		 428

    FTD / Avg. Volume

    n/a
    		 0.08%

    Short Selling Information

    The latest short interest is 1.88M, so 4.16% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.88M

    Short % of Shares Out

    n/a
    		 4.16%

    Short % of Float

    n/a
    		 5.46%

    Short Ratio (days to cover)

    n/a
    		 4.01

    Valuation Ratios

    The PE ratio is 13.34 and the forward PE ratio is 9.64. United Therapeutics's PEG ratio is 0.52.

    PE Ratio

    n/a
    		 13.34

    Forward PE

    n/a
    		 9.64

    PS Ratio

    n/a
    		 5.54

    Forward PS

    n/a
    		 3.2

    PB Ratio

    n/a
    		 2.47

    P/FCF Ratio

    n/a
    		 14.76

    PEG Ratio

    n/a
    		 0.52
    Financial Ratio History

    Enterprise Valuation

    United Therapeutics has an Enterprise Value (EV) of 14.55B.

    EV / Sales

    n/a
    		 5.06

    EV / EBITDA

    n/a
    		 8.8

    EV / EBIT

    n/a
    		 10.96

    EV / FCF

    n/a
    		 13.47

    Financial Position

    The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.05.

    Current Ratio

    n/a
    		 5.25

    Quick Ratio

    n/a
    		 5.03

    Debt / Equity

    n/a
    		 0.05

    Debt / EBITDA

    n/a
    		 0.18

    Debt / FCF

    n/a
    		 0.28

    Interest Coverage

    n/a
    		 32.1

    Financial Efficiency

    Return on Equity is 18.55% and Return on Invested Capital is 16.14%.

    Return on Equity

    n/a
    		 18.55%

    Return on Assets

    n/a
    		 16.23%

    Return on Invested Capital

    n/a
    		 16.14%

    Revenue Per Employee

    n/a
    		 $2,204,904.21

    Profits Per Employee

    n/a
    		 $915,785.44

    Employee Count

    n/a
    		 1,305

    Asset Turnover

    n/a
    		 0.39

    Inventory Turnover

    n/a
    		 1.96

    Taxes

    Income Tax

    n/a
    		 343.9M

    Effective Tax Rate

    n/a
    		 22.35%

    Stock Price Statistics

    The stock price has increased by -2.95% in the last 52 weeks. The beta is 0.57, so United Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.57

    52-Week Price Change

    n/a
    		 -2.95%

    50-Day Moving Average

    n/a
    		 300.31

    200-Day Moving Average

    n/a
    		 340.58

    Relative Strength Index (RSI)

    n/a
    		 40.68

    Average Volume (20 Days)

    n/a
    		 530,658

    Income Statement

    In the last 12 months, United Therapeutics had revenue of 2.88B and earned 1.2B in profits. Earnings per share was 26.44.

    Revenue

    n/a
    		 2.88B

    Gross Profit

    n/a
    		 2.57B

    Operating Income

    n/a
    		 1.38B

    Net Income

    n/a
    		 1.2B

    EBITDA

    n/a
    		 1.65B

    EBIT

    n/a
    		 1.58B

    Earnings Per Share (EPS)

    n/a
    		 26.44
    Full Income Statement

    Balance Sheet

    The company has 1.7B in cash and 300M in debt, giving a net cash position of 1.4B.

    Cash & Cash Equivalents

    n/a
    		 1.7B

    Total Debt

    n/a
    		 300M

    Net Cash

    n/a
    		 1.4B

    Retained Earnings

    n/a
    		 7.22B

    Total Assets

    n/a
    		 7.74B

    Working Capital

    n/a
    		 3.22B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 1.33B and capital expenditures -246.5M, giving a free cash flow of 1.08B.

    Operating Cash Flow

    n/a
    		 1.33B

    Capital Expenditures

    n/a
    		 -246.5M

    Free Cash Flow

    n/a
    		 1.08B

    FCF Per Share

    n/a
    		 23.91
    Full Cash Flow Statement

    Margins

    Gross margin is 89.24%, with operating and profit margins of 47.86% and 41.53%.

    Gross Margin

    n/a
    		 89.24%

    Operating Margin

    n/a
    		 47.86%

    Pretax Margin

    n/a
    		 53.49%

    Profit Margin

    n/a
    		 41.53%

    EBITDA Margin

    n/a
    		 57.5%

    EBIT Margin

    n/a
    		 47.86%

    FCF Margin

    n/a
    		 37.55%

    Dividends & Yields

    UTHR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 7.49%

    FCF Yield

    n/a
    		 6.78%
    Dividend Details

    Analyst Forecast

    The average price target for UTHR is $375, which is 30.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $375

    Price Target Difference

    n/a
    		 30.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 13
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $470.9

    Lynch Upside

    n/a
    		 63.33%

    Graham Number

    n/a
    		 291.23

    Graham Upside

    n/a
    		 1.01%

    Stock Splits

    The last stock split was on Sep 23, 2009. It was a forward split with a ratio of 2:1.

    Last Split Date

    n/a
    		 Sep 23, 2009

    Split Type

    n/a
    		 forward

    Split Ratio

    n/a
    		 2:1

    Scores

    Altman Z-Score

    n/a
    		 12.16

    Piotroski F-Score

    n/a
    		 8

    Add to Watchlist